MEDICAMENT



MEDICAL MARIJUANA RESEARCH NEWSLETTER

WINTER 2022

WELCOME TO MEDICAMENT,

the Consortium for Medical Marijuana Clinical Outcomes Research's quarterly newsletter.

The Consortium, founded by the State of Florida, conducts, disseminates, and supports research on the use and effects of medical marijuana on patient outcomes.

In the Winter 2022 issue of MEDICAMENT:

- Research Grants Program
- Cannabis Clinical Outcomes Research Conference (CCORC)
- Consortium LInkedIn Account
- Medical Marijuana and Me (M³)
- Evidence and Research Announcements
- Publishing Fee Waiver
- · Get Involved in Research



To learn more about the Consortium and our programs, visit us at mmjoutcomes.org.

RESEARCH GRANTS PROGRAM

2023 Grants Program: Letter of Intent NOW OPEN

The Consortium for Medical Marijuana Clinical Outcomes Research announced the Request for Proposals (RFP) for the 2023 Research Grants Program on October 31st, 2022.

Researchers interested in applying to the 2023 Research Grants Program must complete the required <u>online Letter of Intent (LOI)</u> <u>Submission Form</u> by 11:59 PM EST, February 1st, 2023.

Read more about the Request for Proposals (RFP) for the 2023 Research Grants Program >

SUBMIT LETTER OF INTENT

SAVE THE DATE: CCORC 2023



STAY IN TOUCH FOR CCORC 2023 UPDATES

CCORC 2023: SUBMISSIONS OF ORIGINAL RESEARCH ABSTRACTS AND SYMPOSIUM/WORKSHOP PROPOSALS COMING SOON

Deadline for submissions: February 17th, 2023

The Consortium is soon to be accepting submissions of original research abstracts for podium or poster presentation at the Cannabis Clinical Outcomes Research Conference (CCORC) on May 18-19, 2023. Submission of case reports is permissible as are works in progress. Abstracts assessing clinical outcomes of medical marijuana will be granted priority.

New this year is a call for proposals of symposia, workshops or panel discussions for the conference program. These sessions can address topics relevant to researchers, clinicians and policy makers and address topics like new methodologies, lessons learned, clinical or research challenges, evidence summaries and more.

ABSTRACT/SYMPOSIA SUBMISSION DETAILS

MEDICAL MARIJUANA & ME (M3) UPDATE

M³ Study Data Access Coming Soon

Researchers will soon have the opportunity to access cross-sectional data from a cohort of current medical marijuana patients in the Medical Marijuana & Me (M³) Study. These data are available for researchers addressing questions within the following suggested domains (among others):

- Change in Prescription Medications Use
- Change in Substance Use
- Change in Use Patterns Over Time
- Health Outcomes Trajectories
- Most Effective Use Patterns
- MMJ-Related Adverse Effects
- MMJ Use Persistence or Discontinuation
- Potential MMJ-Drug Interactions

The Data Access Request Application is now open for submissions. More information, and a summary of research that has already been proposed, are available at mmjoutcomes.org/m3study.

If you have questions or would like to speak to a study team member, you may call/text (352) 658-3735 or email m3cohort@phhp.ufl.edu.

THE CONSORTIUM: NOW ON LINKEDIN

Stay up to date on the latest research and news related to medical marijuana from the Consortium's member institutions.



MMJ researchers, physicians, and patients can now connect with the Consortium via our official LinkedIn page.

Connect with the Consortium here >

EVIDENCE AND RESEARCH ANNOUNCEMENTS

What Drives Clinical Decision-Making by Medical Marijuana Physicians in Florida? New Study by Consortium-Affiliated Researchers Provides Insight


A recently published study conducted by a team of Consortium-affiliated researchers at the University of Florida offers new insight into the effect patient characteristics have on the clinical decision-making process for MMJ physicians in Florida. Following ten qualitative interviews with certified physicians, the researchers found five major patient characteristics that influenced physician recommendations: patient medical history, co-medications, lifestyle, marijuana experience level, and contra-indications.

Rather than prescribing specific doses and routes to patients, the interviews revealed that physicians combined these five patient characteristics to guide individualized education and recommendations provided to each patient.

Read the full article >

PUBLISHING FEE WAIVER FOR CONSORTIUM-MEMBER INSTITUTIONS

Consortium's Official Journal Offers 50% Off on Article Processing Charges for Accepted Papers from its Member Institutions



Researchers at Consortium-member institutions are encouraged to submit articles for publication in Medical Cannabis and Cannabinoids, an open access journal indexed by PubMed Central and the official journal of the Consortium for Medical Marijuana Clinical Outcomes Research.

All corresponding authors from our nine member universities will receive an automatic 50% discount on article processing charges once accepted for publication in the journal.

To ensure your 50% ACP fee waiver, we recommend including in your submission cover letter that you are from one of the Consortium's member institutions.

For more information about the journal, visit karger.com/mca

GET INVOLVED IN RESEARCH

CARMMA: Changing the way we collaborate across the state of Florida

The Connect and Advance Research for Medical Marijuana Analysis (CARMMA) Database is accessible to researchers, physicians, and industry collaborators.

We believe collaborations bring research advancements. The CARMMA Database connects researchers, clinicians, and industry to foster medical marijuana research.

Anyone interested in engaging in medical marijuana research is invited to register in CARMMA to find collaborators.

JOIN THE CARMMA DATABASE



Have news or feedback to share? Let us know!

Share your Consortium-related research and news through our submission form.

Share your comments on our newsletter through our feedback form.

Don't want to miss any **MEDICAMENT** issues?

Share your contact information through our newsletter sign-up form.

Read previous MEDICAMENT issues on our website.

